Related Experiment Videos
Pharmacotherapy of the depressed patient with cardiovascular and/or cerebrovascular illness
R M Lane1, M Sweeney, J A Henry
1International Pharmaceuticals Group, Pfizer Inc, New York 10017-5755.
Insights
Depression often co-occurs with cardiovascular and cerebrovascular diseases but is frequently untreated. Selective serotonin reuptake inhibitors (SSRIs) offer a safer alternative to tricyclic antidepressants for these patients.
Area of Science:
- Cardiology
- Neurology
- Psychiatry
Background:
- Cardiovascular and cerebrovascular diseases frequently co-occur with depressive disorders.
- This comorbidity is often unrecognized and untreated, worsening patient prognosis and increasing healthcare costs.
- Traditional tricyclic antidepressants pose risks due to cardiac side effects in these patients.
Purpose of the Study:
- To evaluate the therapeutic potential of 5-HT reuptake inhibitors (SSRIs) in patients with cardiovascular or cerebrovascular disease and comorbid depression.
- To highlight the advantages of SSRIs over traditional antidepressants in this specific patient population.
Main Methods:
- Review of pharmacological profiles and side-effect data of SSRIs and tricyclic antidepressants.
- Analysis of clinical relevance in patients with cardiovascular or cerebrovascular disease and depression.
Main Results:
- SSRIs demonstrate favorable side-effect profiles with minimal cardiac effects, no orthostatic hypotension, and reduced toxicity in overdose.
- SSRIs exhibit a lower potential for drug interactions compared to traditional antidepressants.
- These characteristics suggest SSRIs may be a more suitable treatment option for comorbid depression in cardiovascular and cerebrovascular disease patients.
Conclusions:
- Selective serotonin reuptake inhibitors (SSRIs) present a safer and potentially more effective treatment option for depression in patients with cardiovascular and cerebrovascular diseases.
- The favorable safety and drug interaction profiles of SSRIs are clinically relevant for managing this high-risk patient group.
Abstract:
Cardiovascular and cerebrovascular disease are associated with a high incidence of depressive disorder. Despite this high level of co-morbidity, depressive disorders appear to go largely unrecognised and remain untreated. This may have serious consequences, as concomitant depression worsens the prognosis in patients with cardiovascular or cerebrovascular disease, increases medical costs, and delays return to work. Treatment with traditional tricyclic antidepressants is difficult in these patients because of the known cardiac effects. The favourable side-effect profiles of the 5-HT reuptake inhibitors suggest that they may offer therapeutic advantages, as they have little or no effect on cardiac conduction, do not cause orthostatic hypotension, and lack serious sequelae in overdose. The pharmacological profiles and the reduced potential of these newer antidepressant drugs to cause drug interaction show important differences that may be of clinical relevance in this patient population.